Varenicline has been assigned to pregnancy category C by the FDA. Animal studies have failed to reveal evidence of teratogenicity. Animal studies have reported reduced fetal weights, decreased fertility, and increased auditory startle response. There are no controlled data in human pregnancy. Varenicline should only be administered during pregnancy when the potential benefit outweighs the risk.